Earnings
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
CEO Sue Nabi says Coty has created a “multi-functional, stand-alone organization” within its Consumer Beauty business to drive rapid-fire innovation. In a 20 August presentation, Nabi said the firm’s innovation pipeline undergirds its fiscal 2025 outlook of 6%-8% growth.
The beauty giant expects organic sales growth for fiscal 2025 to range between -1% and 2%, falling well short of analyst consensus of 7.2%, reflecting the firm’s overexposure in China and Asia travel retail. A new CEO is incoming with Fabrizio Freda set to step down in June 2025.
Marking a first for the iconic brand, Eucerin Face is rolling out in Target doors now, Beiersdorf leaders noted in a 7 August half-year earnings presentation. The firm’s Consumer business segment recorded nominal sales growth of 5.4% to €4.3bn in the first half of 2024, led by Nivea.
Since its launch of e.l.f. UP! last year on gaming platform Roblox, e.l.f. Beauty has achieved the number one branded experience on the platform with a 95% positive rating and 14 million plays. The firm’s fiscal first-quarter sales jumped 50% to $324.5m.
“We continue to believe that taking care of your health or someone in your family is the last place to look to make a change or save a few pennies,” says CEO Ron Lombardi. Firm more frequently using air freight services so Clear Eyes products are on store shelves when consumers expect.
Inter Parfums, Inc.’s second quarter sales grew 11% on “robust” fragrance environment, strength of legacy brands and speedy ramp-up of new brands, CEO Jean Madar said. Meanwhile, Symrise’s Scent & Care division sales grew 12.1% in the 2024 first half, while Givaudan’s fragrance and beauty sales jumped 15.3%. More fragrance news.
Church & Dwight’s slower sales at retail in June-July than in January-May point to still slower results for rest of year. It doesn’t expect second-half help from gummy vitamin lines or give them a full vote of confidence for remaining in portfolio.
L’Oréal's European business recorded sales growth of 9.7% to €3.55bn in the second quarter as consumer confidence grows, while in the US sales slowed for the dermatological beauty business and consumers in China are value-shopping.
Brimonidine tartrate eye drops remain key sales driver among Canadian firm’s consumer health lines with 12% growth in the latest quarter. B+L expects pending launch of preservative-free line extension to sustain Lumify as a driver as generics of original formulation are approved.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
Unilever hopes to double the value of its product innovations this year, ultimately targeting as many as 12 innovations, each costing more than €100m, beginning in 2025, CEO Hein Schumacher says during 25 July earnings presentation.
Recent announcements at e.l.f. Beauty include the launch of a Keys Soulcare theme on Amazon Alexa that allows users to hear inspiring words and receive beauty and wellness tips from Alicia Keys, plus the company’s introduction of real-world commerce on the Roblox gaming platform.
Major Europe-based consumer health players Sanofi, Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q2 2024 results over the coming weeks.
Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.
More than a decade after acquiring vitafusion and L’il Critter gummy vitamin brands and touting gummy as a key growth driver in the VMS space, C&D’s seeing different market trends.
For Kenvue, 2023 “was really about separating from J&J” as a segment “mostly focused on profit and cash,” says CEO Thibaut Mongon. “But in 2024, you see a very different Kenvue in action.”
The Cincinnati, OH-based consumer goods giant’s Shailesh Jejurika, chief operating officer, presented P&G’s superiority successes in Enterprise Markets at the Deutsche Bank dbAccess Global Consumer Conference.